Compass Therapeutics Faces Mixed Survival Data for Tovecimig in Biliary Tract Cancer Trial

According to a recent LinkedIn post from BioSpectator Inc, Compass Therapeutics has released additional efficacy data from its COMPANION-002 phase 2/3 trial of DLL4xVEGF bispecific antibody tovecimig in second-line biliary tract cancer. The post highlights that the tovecimig combination arm showed a clear progression-free survival benefit, reducing the risk of disease progression or death by 56% versus control (HR 0.44, p<0.0001). However, the LinkedIn commentary notes that overall survival (OS) data are more complex, with the tovecimig plus paclitaxel arm numerically shorter than paclitaxel alone (OS HR 0.15, p=0.78). Compass is reportedly attributing this to a high crossover rate, as 54% of patients in the control arm later received tovecimig, which can confound OS comparisons. According to the post, a subgroup analysis of the control cohort suggested OS of 12.8 months for patients who eventually received tovecimig versus 6.1 months for those who did not (HR 0.54, p=0.04). The commentary indicates that the mixed OS picture introduces uncertainty around the approval prospects of tovecimig as a second-line biliary tract cancer therapy. The post suggests Compass plans roughly a month of further data analysis followed by a mid-summer pre-BLA meeting with the U.S. FDA aimed at pursuing a “meaningful discussion.” If the process proceeds as outlined, a biologics license application could be filed within the year, with a potential regulatory decision in the second half of next year, a timeline that may be closely watched by investors tracking Compass’s oncology portfolio and competitive positioning in biliary tract cancer.